AP NEWS
Click to copy
Press release content from BusinessWire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from BusinessWire
Press release content from BusinessWire. The AP news staff was not involved in its creation.

Symboli Announces Former U.S. Ambassador and Former Deputy Director at FDA to Its Board

December 22, 2018

LOS ANGELES--(BUSINESS WIRE)--Dec 21, 2018--Symboli announces exciting new Board members: U.S. Ambassador Hans H. Hertell and Rikin Mehta

Hans H. Hertell, Esq.

Former U.S. Ambassador Hans H. Hertell, Esq. is an attorney with over 30 years’ experience in government, public affairs, business, and banking. He was the U.S. Ambassador to the Dominican Republic from 2001 to 2007. He received the prestigious Cobb Award for Excellency in Diplomacy by the Department of State. He is Chairman & CEO of The Hertell Group, an international merchant bank. Prior he was Managing Director for Latin America and the Caribbean for Black, Kelly, Scruggs and Healey, a D.C. government and public affairs company. He was President of publicly traded Ponce Federal Bank (NYSE), and a founding partner of the third largest law firm in Puerto Rico. He served on the Board of Directors of the Federal Home Loan Bank of New York.

Rikin Mehta, JD

Rikin Mehta is the Head of Regulatory Affairs for Aquestive Therapeutics where he leads regulatory law and affairs for medical product and drug development efforts. Mehta served as Head of US Regulatory Policy for Pfizer Consumer Healthcare. Prior, he served in a political appointment as the Senior Deputy Director for the Health Regulation and Licensing Administration for the DC Department of Health, where he oversaw implementation of cannabis regulations for D.C. He served as the Deputy Director for the Division of Medical Policy Programs at the Center for Drug Evaluation and Research (CDER), Office of Medical Policy at the U.S. Food and Drug Administration (FDA). There Mehta created and led an initiative exploring regulatory methods to alleviate the under-treatment of common conditions or diseases through the use of innovative technologies or other conditions of safe use to expand access to medications along with ensuring industry compliance for the drug approval process. “I am an incisive, proactive, and highly analytical expert in health and pharmaceutical regulatory affairs, law and policy with years of progressive leadership experience in U.S. state, federal and global markets.”

www.symboli.com Telegram:  t.me/IcQoK0sqIk LinkedIn:  https://www.linkedin.com/company/18913923/admin Twitter:  https://twitter.com/symbolicoin

View source version on businesswire.com:https://www.businesswire.com/news/home/20181220005927/en/

CONTACT: Media Contact:

Parni Bali

parni.bali@symboli.com

+1-800-610-8882Investor Contact:

Peter Brian

peter.brian@symboli.com

+1 800-610-8882

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: HEALTH ALTERNATIVE MEDICINE PROFESSIONAL SERVICES OTHER PROFESSIONAL SERVICES COMMUNICATIONS PUBLIC RELATIONS/INVESTOR RELATIONS

SOURCE: Symboli

Copyright Business Wire 2018.

PUB: 12/21/2018 07:16 PM/DISC: 12/21/2018 07:16 PM

http://www.businesswire.com/news/home/20181220005927/en

All contents © copyright 2019 The Associated Press. All rights reserved.